Abstract | BACKGROUND: METHODS: In this open-label randomised trial in Rarieda district of western Kenya, we enrolled school children (aged 6-15 years) who had Schistosoma mansoni infection according to duplicate Kato-Katz thick smears from a stool sample. Computer-generated block randomisation was used to assign children (1:1) to receive artesunate (100 mg) with sulfalene (also known as sulfamethoxypyrazine; 250 mg) plus pyrimethamine (12.5 mg) as one dose every 24 h for 3 days or one dose of praziquantel (40 mg/kg per day). The primary efficacy endpoint was the number of participants cured 28 days after treatment. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01054651. RESULTS: INTERPRETATION:
|
Authors | Charles O Obonyo, Erick M O Muok, Pauline N M Mwinzi |
Journal | The Lancet. Infectious diseases
(Lancet Infect Dis)
Vol. 10
Issue 9
Pg. 603-11
(Sep 2010)
ISSN: 1474-4457 [Electronic] United States |
PMID | 20705516
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright (c) 2010 Elsevier Ltd. All rights reserved. |
Chemical References |
- Amebicides
- Antiprotozoal Agents
- Artemisinins
- Artesunate
- Sulfalene
- Pyrimethamine
|
Topics |
- Adolescent
- Amebicides
(adverse effects, therapeutic use)
- Animals
- Antiprotozoal Agents
(adverse effects, therapeutic use)
- Artemisinins
(adverse effects, therapeutic use)
- Artesunate
- Child
- Child, Preschool
- Drug Therapy, Combination
- Female
- Humans
- Infant
- Kenya
- Male
- Pyrimethamine
(adverse effects, therapeutic use)
- Schistosoma mansoni
- Schistosomiasis mansoni
(classification, drug therapy)
- Sulfalene
(adverse effects, therapeutic use)
|